CAS - UAB



July, 2016CURRICULUM VITAEAurelio Galli, Ph.D.Home Address: 6560 Banbury Crossing Brentwood TN, 37027 (615) 837-4473Business Address: Vanderbilt Univ. Department of Mol. Physiol. and Biophy. Nashville, TN 37232 Phone (615) 936-3891 Fax (615) 936-3745 E-Mail: Aurelio.Galli@Vanderbilt.edu EDUCATION10/98 Ph.D., Department of Physiology and Biochemistry,State University of Milan, Milan, Italy.7/91 D.Sc., Department of Physiology and Biochemistry,State University of Milan, Milan, Italy.(Advisor: Arnaldo Ferroni, M.D., Ph.D.)Thesis Title: "Ability of Ca2+ Channels to Carry Current During the Nervous Action Potential".EMPLOYMENT EXPERIENCE2014- Associate Director for Research Strategy for the Vanderbilt Brain Institute2012- Director of the Neuroscience Program in Substance Abuse (N-PISA) 2010- Professor, Dept of Molecular Physiology and Biophysics, Vanderbilt University7/05- 2010 Associate Professor; Department of Mol. Physiol. and Biophy. Vanderbilt University Nashville, TN 8/02 – 7/05 Assistant Professor; Department of Mol. Physiol. and Biophy. Vanderbilt University Nashville, TN 3/99 – 8/02 Assistant Professor; Department of Pharmacology, University of Texas at San Antonio, H.S.C. San Antonio, TX 5/95 - 3/99Research Instructor; Department of Pharmacology,Vanderbilt University Nashville, TN9/93 - 4/95Visiting Scientist; Department of Anatomy And Cell Biology, Emory UniversityAtlanta, GA7/91 - 8/92Research Associate, Department of Neuropharmacology,Institute of Pharmacological Research, "Mario Negri"Milan, Italy8/89 - 2/91Teaching Assistant, Department of Physiology and Biochemistry, State University of Milan Milan, ItalyACADEMIC COMMITTEES6/2016- Vanderbilt Brain Institute Directorship Search Committee06/09-09/09 IGP Review Committee05/09-04/10 Investigating Committee School of Engineering/misconduct case 09/08- 09/09 DRTC Search Committee 03/08 Bridge Feasibility Committee01/08-08/08 Dept. of Pharmacology Search Committee01/07-08/09 Spickard Addiction Chair Search Committee03/07 Basic Science Department Discussion06/04 - Departmental Committee. Review of Qualifying Exam Abstracts04/04 - Departmental Committee on Graduate Studies (GEC)03/05 LCME Site Visit Committee2/04 Vanderbilt VUMC Intramural Discovery Grant Program 12/03 Vanderbilt VUMC Intramural Discovery Grant Program 04/03 – 06/03 Vanderbilt DANA Proposal Planning Committee. Planning of an Interdisciplinary proposal to be submitted to the DANA foundat. 08/02 – 12/02 Conference Planning Committee. Vanderbilt University Summer Conferences: “Frontiers in addiction biology: Genomics and beyond”. 03/02 U.T.H.S.C.S.A. Departmental Committee on Faculty Development08/01 – 06/02 U.T.H.S.C.S.A. Departmental Committee on Graduate Studies04/01 – 07/01 U.T.H.S.C.S.A. Coordinator of International Services Search Committee10/99 – 10/01 U.T.H.S.C.S.A. Seminar Series Coordinator11/00 – 1/01 U.T.H.S.C.S.A. Departmental Web Page Committee02/00 – 04/01 U.T.H.S.C.S.A. Departmental Plan Committee (Brain Bowl)TEACHING EXPERIENCE08/16-05/16 Course Director “Neurobiology of Addiction” Undergraduate class (54 lectures). 04/16 Lecture for undergraduate students; “Molecules of the Brain” Vanderbilt University, Nashville, TN.3/2016 Vanderbilt Association of Neuroscience and Law (Special Lecture) 04/16 Lecture for undergraduate students; “Dopamine and Addiction” Vanderbilt University, Nashville, TN.1/2016 NRSA proposal external reviewer (Corey Roach) 9/15-12/15 MLI 6025 (Nicole Bibus Christianson, Independent Study)01/15-05/15 Course Director “Neurobiology of Addiction” Undergraduate class (27 lectures).04/09-04/14 Course Director “Electrophysiology for Biologist” Graduate IGP class.03/08 Lecture for graduate students; “IGP Neuroscience” Vanderbilt University, Nashville, TN.01/07 Lecturer for graduate students; "FlexTime Group” Vanderbilt University, Nashville, TN. 03/06 Lecturer for graduate students; "Psychotropic Drugs Course". Vanderbilt University, Nashville, TN.01/06 Lecturer for medical students; "Medical Physiology” Vanderbilt University, Nashville, TN. 03/05 Lecturer for graduate students; "Psychotropic Drugs Course". Vanderbilt University, Nashville, TN.01/05 Independent Study; Liza Nikandrova, MPB Graduate Student. Vanderbilt University, Nashville, TN.01/05 Lecturer for medical students; "Medical Physiology” Vanderbilt University, Nashville, TN. 02/05 Lecturer for graduate students; "Excitable Membrane Class” Vanderbilt University, Nashville, TN. 09/04 – 08/05 Provocateur; Neuroscience Research Forum. Vanderbilt University, Nashville, TN.04/04 Lecturer for sophomores; "Research Explorers” Vanderbilt University, Nashville, TN.04/04 Chair; "Introduction to Biomedical Research” Vanderbilt University, Nashville, TN. 01/04 Lecturer for graduate students; "FlexTime Group” Vanderbilt University, Nashville, TN. 01/04 Lecturer for medical students; "Medical Physiology” Vanderbilt University, Nashville, TN. 09/03 – 08/04 Provocateur; Neuroscience Research Forum. Vanderbilt University, Nashville, TN.12/03 Lecturer for graduate students; "I.G.P. Neuroscience Section” Vanderbilt University, Nashville, TN. 01/03 – 02/03 Lecturer for graduate students; "Psychotropic Drugs Course". Vanderbilt University, Nashville, TN.09/02 – 12/02 Provocateur; Molecular Neuroscience Journal Club. Vanderbilt University, Nashville, TN.06/01 Lecturer for undergraduate students; “Pharmacology Laboratory” University of Texas H.S.C. San Antonio.8/01 - 12/01Lecturer for graduate students; "Cell and Molecular Physiology". University of Texas H.S.C. San Antonio.08/01 Lecturer for Post Docs; "Lab. Management". University of Texas H.S.C. San Antonio.04/01 Lecturer for graduate students; "Molecular Pharmacology". University of Texas H.S.C. San Antonio.8/00 - 12/00 Lecturer for graduate students; "Cell and Molecular Physiology". University of Texas H.S.C. San Antonio.8/99 - 12/99 Lecturer for graduate students; "Cell and Molecular Physiology". University of Texas H.S.C. San Antonio.2/97 - 3/97 Lecturer for graduate students; "Excitable Membranes". Vanderbilt University, Nashville, TN.11/96 - 11/97 Provocateur; Graduate Student Weekly Seminar Series.Vanderbilt University, Nashville, TN.1/96 - 1/97Training course in electrophysiology for graduate students.Vanderbilt University, Nashville, TN.9/93 - 4/95Training course in electrophysiology for graduate students.Emory University, Atlanta, GA.1/92 - 3/92Lecturer, "General Physiology II"Department of Physiology and Biochemistry, State University of Milan, Milan, ItalyQUALIFYNG EXAMS20051. Brad Alan Grueter. M.P.B. Vanderbilt University2. Butch Granada. M.P.B. Vanderbilt University3. Yelyzaveta Nikandrova. Vanderbilt University4. Sepan Amadi. Vanderbilt University20065. Heather Gosnell. Vanderbilt University6. Angela Shields. Vanderbilt University7. Mengnan Tian. Vanderbilt University8. David Lund. Vanderbilt University9. Julie Field. Vanderbilt University200710. Ezelle Teresa McDonald. Vanderbilt University11. Laurel Hoffman. Vanderbilt University12. Sonya Dave. Vanderbilt University13. Dhananjay Sakrikar. Vanderbilt University200814. Alessandro Ustione15. Bill Nobis16. Patrick Jones17. Heidi Kocalis200918. Marquicia Reginee Pierce19. Marc Andrew Mergy20. Charles Asher Day201021. Rachel Lippert22. Nora Kayton23. Jinlong Ding201124. Megan Fettig25. Matthew Parkinson 201326. Gwynne Davis2014Alyssa D. LokitsDOCTORAL, HONORS, THESIS COMMITTEES1. Amanda Vanhoose. M.P.B. Vanderbilt University.2. Brad Alan Grueter. M.P.B. Vanderbilt University. 3. Kevin Choo. Vanderbilt University. (Masters committee).4. Michelle Suzanne Mazei. Pharmacology. Vanderbilt University.5. Daniele Provenzano. Microbiology. U.T.H.S.C.S.A.6. Kris M. Kahlig. Ph.D. Advisor. Pharmacology. U.T.H.S.C.S.A.7. Jasmine Ferrer. Center for Molecular Recognition. Columbia University.8. Rajkumar Sevak. Pharmacology. University of Texas HSCSA. 9. Leomar Ballester. Pharmacology. Vanderbilt University.10. Jennifer Steiner. Neuroscience. Vanderbilt University.11. Adeola Davis. Physiology. Vanderbilt University.12. Erica Bowton. Neuroscience. Vanderbilt University.13. Julie Field. Neuroscience. Vanderbilt University.14. Derek Claxton. Physiology. Vanderbilt University.15. Angela Shields. Physiology. Vanderbilt University.16. Patrick Jones. Biological Sciences. Vanderbilt University.17. Peter Chisnell. Interdisciplinary Program In Neuroscience. Vanderbilt University18. Heather Gosnell. Physiology. Vanderbilt University.19. Alessandro Ustione. Physiology. Vanderbilt University. 20. Laurel Hoffman. Physiology. Vanderbilt University.21. Mengnan Tian. Pharmacology. Vanderbilt University.22. Dhananjay Sakrikar. Neuroscience. Vanderbilt University.23. Christopher Divito. Neuroscience. University of Pittsburg.24. Patrick Jones. Biological Sciences. Vanderbilt University.25. Marc Mergy. Neuroscience. Vanderbilt University.26. Pask Gregory Mark. Biological Sciences. Vanderbilt University.27. Marquicia Pierce. Physiology. Vanderbilt University.28. Rachel Lippert. Physiology. Vanderbilt University.29. Andrew Hardaway. Neuroscience. Vanderbilt University.24. Parkinson, William Matthew. Biological Sciences. Vanderbilt University.25. Courtney, Patrick Travis. Honors Thesis Committee. Vanderbilt University.In progressElizabeth Anne Ferrick. Physiology. Vanderbilt University.Isaac, Austin Thomas. Honors Thesis Committee. Vanderbilt University.Morrow-jones, Dylan. Neuroscience. Vanderbilt University. (Chair).Miles Bryan. Neuroscience. Vanderbilt University. (Chair).ADDITIONAL STUDENT TRAINEES1. Brandon Lute. Neuroscience. Vanderbilt University. (Ph.D. Advisor)2. Pedro Francisco Andollo. Neuroscience Undergraduate Vanderbilt University.3. Concetta di Pace. University of Bari.4. Francesca Binda. University of Insubria. 5. Andrea T. Quiroga. Pharmacology. U.T.H.S.C.S.A.6. Thomas M. Austin Jr. I.B.R. Vanderbilt8. Erica Bowton. Neuroscience. Vanderbilt University. (Ph.D. Advisor)9. Kris M. Kahlig. Pharmacology. U.T.H.S.C.S.A. (Ph.D. Advisor)10. Sabrina Doughty. Neuroscience. Vanderbilt. (Ph.D. Advisor)11. Jessica Moore. Neuroscience. Vanderbilt. (Ph.D. Advisor)12. Nicole Speed. Pharmacology. Vanderbilt University. (Ph.D. Advisor)13. Charlie Xie. Nashville, High School MLK. First Place TN, Junior Academy of Science, Second Place Intel International Science and Engineering Fair. 14. Soora, Raksha. University of Arkansas, Medical school. (Summer Advisor). 15. Vidiya Sathananthan. Boston University. (Summer Advisor).16. Pouya Gharahdaghi. Howard University College of Medicine. (Summer Advisor). 17. Kurt Niesner. University of Tennessee Health Science Center Medical School. (Research Advisor).18. Michael Siuta. MSTP Program. Vanderbilt University. (Ph.D. Advisor)19. Michelle Shung. Vanderbilt University. Undergraduate Research Fellow.20. Catherine Elaine Emery. Vanderbilt University. Aspirnaut Summer Research High School Intern.21. Catherine Nettesheim. Vanderbilt University. Undergraduate Research Fellow.?22. India Reddy. MSTP Program. Vanderbilt University. (Ph.D. Advisor)23. Pires, Giovanna Rodosli. Vanderbilt University. Undergraduate Research Fellow.?24. Peter Hamilton. Neuroscience. Vanderbilt. (Ph.D. Advisor)25. Olga Dadalko. Neuroscience. Vanderbilt. (Ph.D. Advisor)POSTDOCTORAL FELLOW/RESEARCH ASSOCIATES1. Jose A. Moron2. Lucia Carvelli3. Hongwei Wang4. Habibeh Khoshbouei 5. Francesca Binda6. Concetta DiPace7. Jason Williams8. Kevin Erreger9. Kris Kahlig10. Christine Saunders11. Heinrich J. G. Matthies12. Etienne Cartier13. Adeola Davis14. Nicolas Campbell VISITING SCIENTISTSToni S. Shippenberg. NIDA. Baltimore, MD. Rymond Mohaghegh. Meharry Medical College. Nashville, TN.Timothy Angelotti. Stanford University. Stanford, CA.Craig Gatto. Illinois State University, Normal, IL.ADVISORY COMMITEESAdvisor to Dr. Timothy Angelotti (K08 Award). Assistant Prof. Stanford University. (2004-2007).GRANT REVIEWERNIHNIH Study Section ZDA1RXL-E(18) 2005NIH Study Section ZDA1RXL-E(23) 2005NIH Study Section NTRC (member) 2006-10NIH Study Section BSCT 2006NIH Study Section ZDA1 RXL-E(24) 2006NIH Study Section ZDA1 MXS-M (17) 2007NIH Study Section ZDA1 RXL-E 30 (1) 2007 NIH Study Section ZDA1 RXL-E (11) 2007 NIH/NIDA. CEBRA Program. 2009 Ad Hoc MemberNIH Study Section ZDA1 GXM-A (12) 2013NIH Study Section Peer Review Quality Experiment 2015NIH Study Section NTRC 2015NIH Study Section MNPS 2015NIH Study Section MNPS 2015NIH/NIDA Study Section ZDA1-SXM-M-03 2015NIH Study Section ZRG1-F03B-E-20 2015NIH Study Section ZRG1-F03B-E-21 2015FUNDATIONSAustrian Science Fund (Austrian NIH) 2004-2006Vanderbilt VUMC Intramural Discovery Grant Program. Harry Frank Guggenheim foundation 2005Nicholas Hobbs Discovery Grant 2010VA Merit Award 2011NARSAD (Council Member) 2011Brain and Behavior Research Foundation (Council Member) 2012- Pilot and Feasibility Project. Diabetes Research and Training Center (Vanderbilt). 2016 HONORS AND AWARDSState University of Milan: Laude (110/110) (Thesis Dissertation).Young Investigator at the 20th Biennial Meeting of the International Society for Neurochemistry in Innsbruck. Bursary Recipient, EU TMR Euroconference on Neuronal Transporters. Dublin, Ireland.Freedman Award. For an Outstanding Research. NARSAD. (Honorable Mention).Lyndon Baines Johnson Research Award. Most Outstanding Research. (American Heart Association). NARSAD Young Investigator Award.Howard Hughes Medical Institute Award.Scientific Council, Brain and Behavior Research Foundation (NARSAD).Transformative R01 DK08571209/01/2009-06/30/2015NIH/NIDDK “Insulin Regulation of monoamine signaling: pathway to obesity”.Chair Gordon Research Conference on Membrane Transport Proteins.ACTIVITIESSoutheastern ASPET Meeting: Organizer - September, 1998; Nashville, TNFrontiers in Addiction Biology: Genomics and Beyond: Organizer - May, 2004; Nashville, TNCo-chair slide section Serotonin Transport II, Neuroscience Meeting, October, 2004; San Diego, CA.Mentoring Institute for Neuroscience Diversity Scholars (MINDS) workshop. Mentor- 2015; University of Florida.K99/R00 workshop. Organizer- 2016; Vanderbilt University.EDITORIALBiochemistry, Journal of Neurochemistry, Journal of Biological Chemistry, Journal of Neuroscience, Neuropsychopharmacology, News in Physiological Sciences, Biological Psychiatry, Biophysical Journal, Molecular Pharmacology, European Archives, Neurochemistry International, Neurophysiology, Neuroscience Letters, Neuroscience, Neuropharmacology, Journal of Pharmacology and Experimental Therapeutics, Psychoneuroendocrinology, Diabetologia, Nature Comunications.Member of the Editorial Board of the Journal of Biological Chemistry (July 2012)Member of the Editorial Board of Molecular Pharmacology (July 2012)FUNDINGACTIVERole: PI1R24 R24DK093421-01A1 (Cone/Galli) 09/16/2013-08/31/20151.2 cal monthsNIH/NIDDK$400,000Molecular and Cellular Basis for the Efficacy of Bariatric SurgeryThis multi-investigator team grant will use the Vanderbilt models of RYGB and gastric sleeve bariatric surgery to investigate the molecular and cellular basis for the efficacy of bariatric surgery in sustained weight loss and improved glucose homeostasis.Role: PI1R01 DA035263-01A1 (Galli)04/01/2014-03/31/20193.6 calendar monthsNIH$355,800The dopamine transporter’s lipid interactions: understanding transporter functionGoal: The goal of this project is to determine the role of PIP2 in dopamine transporter functionRole: PI1R21 DA035588-01 (Galli/Stanwood)04/01/2013-03/31/20161.2 calendar monthsNIH$350,000GLP-1 Receptors and Psychostimulant AddictionGoal: To understand the neurobiological mechanisms by which glucagon-related Peptide 1 (GLP-1) receptors alter brain chemistry and may represent a mechanism to treat psychostimulant drug abuse.Role: PI1R01 DA038058-01 (Galli)07/01/2014-06/30/20193.6 calendar monthsNIH$253,287The Role of the Dopamine Transporter in Psychostimulant AbuseGoal: The goal of this project is to determine how casein kinase 2 regulates amphetamine behaviorsRole: PIPast:NARSAD (National Alliance for Research on Schizophrenia and Depression) Young Investigator AwardBeginning Grant-in-Aid, American Heart Association, Texas Affiliate’s Howard Hughes Medical Institute AwardNARSAD Young Investigator AwardPeter F. McManus Charitable TrustRO1 (NIDA) DA14684 (Galli) 09/30/01 - 08/31/06“Molecular mechanisms of stimulant abuse” Role: PIRO1 (NIMH) MH58921 (Galli) 12/011/04-11/30/09Acute Regulation of Norepinephrine TransportersRole: PIRO1 (NIDA) DA011697 (Gnegy) (Galli Subcontract) 9/30/05 - 9/29/10“Pharmacology of Dopamine Release by Amphetamine”Role: CollaboratorTransformative RO1 DK085712-05 (Galli/Niswender) 09/01/2009-06/30/2015 3.3 calendar monthsNIH/NIDDK$653,107Insulin Regulation of monoamine signaling: pathway to obesityThe main goal of this project is to understand the role of insulin in the development of obesity Role: PI5P01 DA012408-14 (Galli)03/01/2004-02/29/2016 1.92 calendar months NIH/NIDA (Subcontract, Cornell)$135,607Specialized Experimental Probing of Structure and Function of Neurotransmitter TransportersThe focus is on characterizing the cellular conditions required for amphetamine (AMPH) to produce modifications of human dopamine transporter (hDAT) activity, as measured by electrical currents.5R01 DK085064-04 (Piston)4/1/2010-03/31/20150.36 calendar monthsNIH/NIDA$198,235Dopamine Action in Pancreatic Islet FunctionThe long term objective of this project is to understand the role of dopamine on insulin releaseRole: Collaborator5R01 MH094527-22 (Blakely)02/01/2011-08/31/20150.6 calendar months NIH$299,268Regulation of Serotonin TransportersThis project explores the ability of cell surface receptors linked to PKC, PKG and p38 MAPK to regulate serotonin transporter proteins using cell culture methods.Role: Collaborator5R01 MH 095044-02 (Blakely)05/01/2012-04/30/20170.6 calendar monthsNIH$240,000Presymaptic Regulation of C. elegans Dopamine TransporterGoal: The goal of this projects is to measure dopamine efflux from dopaminergic neurons obtained from different C. elegans strains.Role: Co-InvestigatorDA013975-13 (Galli)04/01/2001-08/31/20153.6 calendar months NIH/NIDA$225,000Amphetamine Regulation of Dopamine TransportThe major goal of this grant is to characterize the biophysics of the interaction between psychostimulants and the dopamine transporter.Role: PI Fellows with FundingAndrea Belovich: NRSAIndia Reddy: NRSAPastSabrina Doughty: NRSA Nicole Speed: NRSABrandon Lute: NRSAErica Bowton: NRSAKevin Erreger: NRSAPeter Hamilton NRSAKevin Erreger: K99/R00Michael Siuta: NRSA Peter Hamilton: NSFKevin Erreger: NARSADPUBLICATIONSPapers1. Mazzanti, M., Galli, A., Ferroni, A. Increase of firing rate modulates L-type Ca2+ channels in adult neurons. Biophys. J. 63:926-934. (1992).2. Vezzani, A., Monno, A., Rizzi, M., Galli, A., Barrios, M., Samanin, M. Somatostatin release is enhanced in the hippocampus of partially and fully kindled rats. Neuroscience 51:41-46. (1992).3. Galli, A., Ferroni, A., Bertollini, L., Mazzanti, M. Extracellular Ca2+ inactivates single Ca2+ channels in rat sensory neurons. J. Physiol. 477:15-26. (1994).4. Galli, A., DeFelice, L.J. Inactivation of L-type Ca2+ channels in embryonic chick ventricle cells: dependence on the cytoskeletal agents colchicine and taxol. Biophys. J. 67:2296-2304. (1994).5. Galli, A., DeFelice, L.J., Duke, B.J., Moore, K.R., Blakely, R.D. Sodium-dependent norepinephrine-induced currents in norepinephrine transporter transfected HEK293 cells blocked by cocaine and antidepressants. J. Exp. Biol. 198:2197-2212. (1995).6. Galli, A., DeFelice, L.J., Blakely, R.D. Norepinephrine transporters have channel modes of conduction. Proc. Natl. Acad. Sci. USA. 93(16):8671-8676. (1996).7. Ferroni, A., Galli, A., Mazzanti, M. Dihydropyridine sensitive Ca2+ channels open at low voltages after fast depolarization. Pflug. Arch. 431:954-963. (1996).8. Qian, Y., Galli, A., Ramamoorthy, S., Risso, S., DeFelice, L.J., Blakely, R.D. Protein kinase C activation regulates human serotonin transporters in HEK293 cells via altered cell surface expression. J. Neurosci. 17(1):45-47. (1997).9. Galli, A., Petersen, C.I., deBlaquerie, M., Blakely, R.D., DeFelice, L.J. Drosophila serotonin transporters have voltage-dependent uptake and conduct serotonin in a channel mode.J. Neurosci. 17(10):3401-3411. (1997).10. Galli, A., Blakely, R.D., DeFelice, L.J. Patch-clamp and amperometric recordings from norepinephrine transporters: Channel activity and voltage-dependent uptake. Proc. Natl. Acad. Sci. USA. 95(22): 13260-13265. (1998). See commentary PNAS 95(22): 12737-12738. 11. Apparsundaram, S., Galli, A., DeFelice, L.J., Hartzell, H., Blakely, R.D. Acute regulation of norepinephrine transport: Protein kinase C-linked muscarinic receptors influence transport capacity and transport density in SK-N-SH cells. (J.P.E.T.). 287: 733-743. (1998).12. Galli, A., Lankupalle, D.J., Ramsey, I.S., Miller, J.W., Fremeau, R.T., DeFelice, L.J. L-Proline and L-Pipecolate induce enkephalin-sensitive currents in HEK-293 cells transfected with the high affinity mammalian brain L-proline transporter. J. Neurosci. 19(15): 6290-6297. (1999).13. Saunders, C., Ferrer, J.V., Shi, L., Chen, J., Merrill, G., Lamb, ME., Leeb-Lundberg, L.M.F., Carvelli, L., Javith, J.A., Galli, A. Amphetamine-induced loss of human dopamine transporter activity: an internalization-dependent and cocaine-sensitive mechanism. Proc. Natl. Acad. Sci. USA. 97(12): 6850-6855. (2000).14. Carvelli, L., Moron, J., Kahlig, K., Ferrer, JV., Sen, L., Lechleiter, JD. Leeb-Lundberg, LMF, Merrill, G., Lafer, E.M., Ballou, LM., Shippenberg, T., Javitch, JA., Lin, RZ and Galli, A. PI 3-Kinase regulation of dopamine Uptake. Journal of Neurochemistry. 81(4): 859-869. (2002). 15. Daws, L.C., Callaghan, P.D., Morón, J., Kahlig, K.M., Shippenberg, T.S., Javitch, J.A., Galli, A. Cocaine-evoked trafficking of the dopamine transporter causes a time-dependent increase in dopamine uptake. Biochemical and Biophysical Research Communications 290: 1545-1550 (2002).16. Clemons, A.P., Holstein, D.L., Galli, A., Saunders, C. Inhibition of MEK1/2 by PD98059 and UO126 rescues cerulein-induced acute pancreatitis in the rat. Pancreas 25(3):251-9 (2002)17. Galici, R., Galli, A., Jones, D.J., Sanchez, T.A., Saunders, C., Frazer, A., Gould, G.G., Lin, R.Z., France, C.P. Selective decreases in amphetamine self-administration and regulation of dopamine transporter function in diabetic rats. Neuroendocrinology 77(2): 132-140. (2003). 18. Morón, J., Ferrer, J.V., Merrill, GA., Uhl, G., Lafer, E.M., Lin, Z.C., Javitch, J.A., *Galli, A., *Shippenberg, T.S. Regulation of dopamine transporter capacity and cell surface expression by mitogen activated protein kinase. J. Neurosci. 23(24): 8480-8488. (2003). *These authors contributed equally to this work.19. Sung, U., Apparsundaram, S., Galli, A., Kahlig, KM., Savchenko, V., Schroeter, S., Quick, MW., Blakely, R. A regulated interaction of syntaxin 1A with the antidepressant-sensitive norepinephrine transporter establishes catecholamine clearance capacity. J. Neurosci. 23(5): 1697-1709. (2003).20. Khoshbouei, H., Wang, H., Lechleiter, JD., Javitch, JA., Galli, A. Amphetamine-induced DA-efflux: a voltage sensitive and intracellular Na+-dependent mechanism. J. Biol. Chem. 278(14): 12070-12077. (2003). 21. Kahlig, K.M., Javitch, J.A., Galli, A. Amphetamine regulation of the human dopamine transporter activity: a time-dependent trafficking process. J. Biol. Chem. 279(10): 8966-8975. (2004).22. Khoshbouei, H., Sen, N., Guptaroy, B., Johnson, L., Lund, D., Gnegy, M.E., *Galli, A., *Javitch, J.A. N- terminal phosphorylation of the dopamine transporter is required for amphetamine-induced efflux. *These authors contributed equally to this work. PLoS Biology. 2(3): 0387-0393. (2004).23. Gnegy, M. E., Khoshbouei, H., Berg, K. A., Javitch, J. A., Clarke, W. P., Zhang, M., Galli, A. Intracellular Ca2+ regulates amphetamine-induced dopamine efflux and currents mediated by the human dopamine transporter. Mol. Pharm. 66(1): 137-143. (2004).24. Kahlig, K.M., Binda, F., Khoshbouei, H., Blakely, RD., McMahon, DG., Javitch, J.A., Galli, A. Amphetamine induces dopamine efflux through a transporter channel. Proc. Natl. Acad. Sci. 102: 3495-3500. (2005).25. Garcia, B., Wei, Y., Moron, J.A., Javitch, J.A., Lin, R.Z., Galli, A. Akt is Essential for Insulin Modulation of Amphetamine-Induced Human Dopamine Transporter Cell-Surface Redistribution. Mol. Pharm. 68(1): 102-109. (2005).26. Owens, WA., Sevak, RJ., Galici, R., Chang, X., Javors, MA., Galli, A., France, CP., Daws, LC. Deficits in dopamine clearance and locomotion in hypoinsulinemic rats unmask novel modulation of dopamine transporters by amphetamine. J. Neurochem. 94(5): 1402-1410. (2005).27. Binda F., Lute BJ., Dipace C., Blakely, RD., Galli A. The N-terminus of the norepinephrine transporter regulates the magnitude and selectivity of the transporter-associated leak current. Neuropharmacology. 102(9):3495-500. (2006).27. Kahlig KM, Lute BJ, Wei Y, Loland CJ, Gether U, Javitch JA, Galli A. Regulation of dopamine transporter trafficking by intracellular amphetamine. Mol. Pharm. 70(2):542-8. (2006)28. Fog, J.U., Khoshbouei, H., Holy, M., Bjerggaard, C., Bowton, EA., Sitte, H., Colbran, R.J., *Javitch, J.A., *Galli, A., *Gether, U. *These authors contributed equally to this work. Calmodulin kinase II interacts with the dopamine transporter C-terminus to regulate amphetamine-induced reverse transport. Neuron. 51: 417-429. (2006).29. Sevak, RJ., Owens, WA., Galli, A., Daws, LC., France,CP. Evidence for D2 receptor mediation of amphetamine-induced normalization of locomotion and dopamine transporter function in hypoinsulinemic rats. J. Neurochem. 101(1):151-9. (2007).30. Dipace, C., Sung U., Binda F., *Blakely R.D., *Galli A. Amphetamine induces a calcium/calmodulin-dependent protein kinase II-dependent reduction in norepinephrine transporter surface expression linked to changes in syntaxin 1A/transporter complexes. *These authors contributed equally to this work. Mol Pharm. 71(1):230-9. (2007).31. Wei Y., Williams J.M., Javitch J.A., Galli A., Saunders C. Amphetamine, but not cocaine, attenuates Akt activity in hDAT-expressing cells and striatal synaptosomes. Mol Pharm. 71(3):835-842. (2007)32. Sevak, R., Koek, W., Galli, A., France, CP. Insulin replacement restores the behavioral effects of quinpirole and raclopride in streptozotocin-treated rats. JPET. 320(3):1216-23. (2007).33. Williams, J.M, Owens, W.A., Turner, G.H., Blakely, R.D., France, C.P., Gore, J.C., Avison, M.J., Daws, L.C., Galli, A. In vivo effects of insulin on dopaminergic function and amphetamine pharmacology. PLoS Biology. 5(10):2369-78. (2007).34. Erreger, K., Grewer, C., Javitch, JA., Galli, A. Amphetamine induces a rapidly desensitizing inward current through the human dopamine transporter. J. Neurosci. 28(4):976-89. (2008).35. Sevak RJ, Koek W, Daws LC, Owens WA, Galli A, France CP. Behavioral effects of amphetamine in streptozotocin-treated rats. Eur J Pharmacol. 581(1-2):105-12. (2008).36. *Mazei-Robison MS,*Bowton E, Holy M, Schmudermaier M, Freissmuth M, Sitte HH, #Galli A, #Blakely RD. # These authors contributed equally to this work. Dopamine transporter coding variant Ala559Val associated with attention deficit hyperactivity disorder (ADHD) causes alteration of dopamine efflux. J. Neurosci. 28:7040-7046. (2008). Noted in Science, Editor's choice-citation and J. Neurosci, This Week in the Journal.?37. Binda, F., Dipace, C., Bowton, EA., Lute, BJ., Fog, JU., Zhang, M., Sen, N., Colbran, RJ., Gnegy, ME., Gether, U., Javitch, JA, Erreger, K., Galli, A. Syntaxin1A Interaction with the Dopamine Transporter Promotes Amphetamine-Induced Dopamine Efflux. Mol. Pharm. 74(4):1101-8. (2008).38. Sevak RJ., Koek W., Owens WA., Galli A., Daws LC., France CP. Feeding conditions differentially affect the neurochemical and behavioral effects of dopaminergic drugs in male rats. Eur J Pharmacol. 592(1-3):109-15. (2008).39. Lute BJ, Khoshbouei H, Saunders C, Sen N, Lin RZ, Javitch JA, Galli A. PI3K signaling supports amphetamine-induced dopamine efflux. Biochemical and Biophysical Research Communications. 372 (4):656-61. (2008).40. Guptaroy B., Zhang M., Bowton E., Binda F., Shi L., Weinstein H., Galli A., Javitch JA., Neubig RR., Gnegy ME. A juxtamembrane mutation in the N terminus of the dopamine transporter induces preference for an inward-facing conformation. Mol. Pharm. 75(3):514-24. (2009).41. Matthies HJG., Han, Q., Shields, A.D., Wright, J., Moore, J.L., Winder, D.G., Galli, A., and R.D. Blakely. Subcellular Localization of the Antidepressant-Sensitive Norepinephrine Transporter, BMC Neuroscience 10:65. (2009).42. Carvelli, L., Matthies, DS., Galli, A. Uncovering the molecular mechanisms supporting amphetamine actions in C. Elegans. Mol. Pharm. 78(1):151-6. (2010).43. Bowton, E., Saunders, C., Erreger, K., Sakrikar, D., Matthies, HJG., Sen, N., Jessen, T., Colbran, RJ., Caron, MG., Javitch, JA., Blakely, RD., Galli, A. Dysregulation of dopamine transporters via dopamine D2 autoreceptors triggers anomalous dopamine efflux associated with attention-deficit hyperactivity disorder . J. Neurosci. 30(17):6048-6057. (2010).44. Siuta, MA., Robertson, SD, Kocalis, H., Saunders, C., Gresch, PJ., Khatri, V., Shiota, C., Kennedy, JP., Lindsley, CW., Daws, LC., Polley, DB., Veenstra-Vanderweele, J., Stanwood, GD., Magnuson, MA., Niswender, KD., Galli, A. Dysregulation of the norepinephrine transporter sustains cortical hypodopaminergia and schizophrenia- like behaviors in neuronal Rictor null mice. PLoS Biology. 8(6):e1000393. (2010). 45. Matthies, HJG., Moore, J.L., Saunders, C., Matthies, D.S., Lapierre , L.A., Goldenring, J.R., Blakely, R.D., Galli, A. Rab11a supports amphetamine-stimulated norepinephrine transporter trafficking. J. Neurosci. 30:7863-7877. (2010).46. Speed, NK., Matthies, HJG., Kennedy, JP., Vaughan, RA., Javitch, JA., Russo, SJ., Lindsley, CW., Niswender, K., Galli, A. Akt-Dependent and Isoform-Specific Regulation of Dopamine Transporter Cell Surface Expression. ACS Chem. Neurosc. 1 (7), pp 476–481. (2010).47. Robertson, SD., Matthies, HJG., Owens, AW., Sathananthan, V., Bibus Christianson, NS., Kennedy, JP., Lindsley, CW., Daws, LC., Galli, A. Insulin reveals Akt signaling as a novel regulator of norepinephrine transporter trafficking and norepinephrine homeostasis. J. Neurosci. 30(34):11305-11316. (2010).48. Cremona, ML., Matthies, HJ., Pau, K., Bowton, E., Speed, N., Lute, BJ., Anderson, M., Sen, N., Robertson, SD., Vaughan, RA., Rothman, JE., Galli, A., Javitch, JA., Yamamoto, A. Flotillin-1 is essential for PKC-triggered endocytosis and membrane microdomain localization of DAT. Nat Neurosci. 14(4):469-77. (2011).49. Speed, N.K.*, Saunders, C *., Owens, W.A., Saadat, S., Matthies, H.J.G., Kennedy, J., Vaughan, R., Neve, R., Lindsley, C., Russo, S., Daws, L.C., Niswender, K.D*., Galli, A*. Diet-Induced Changes in Insulin Signaling Regulates the Trafficking and Function of the Dopamine Transporter. PLoS One, 6(9): e25169. (2011). 50. Mazei-Robison MS, Koo JW, Friedman A, Lansink CS, Robison AJ, Vinish M, Krishnan K, Kim S, Siuta, MS, Galli A, Niswender KD, Appasani R, Horvath MC, Neve RL, Worley PF, Snyder SH, Hurd YL, Cheer JF, Han MH, Russo S, Nestler EJ. Role for mTOR signaling and neuronal activity in morphine-induced adaptations in ventral tegmental area dopamine neurons. Neuron 72(6):977-90. (2011).51. Owens, WA., Williams, JM., Saunders, C., Avison, MJ., #Galli, A., #Daws, LC. Acute actions of amphetamine are blunted in hypoinsulinemic rats but rescued after repeated exposure to systemically administered amphetamine. # These authors contributed equally to this work. J. Neurosc. 32(8):2637-47. (2012).52. Sakrikar, D., Mazei-Robison, MS., Mergy, MA, Richtand, NW, Han, Q., Hamilton, PJ., Bowton, E., Galli, A., Veenstra-VanderWeele, J., Gill, M., Blakely, RD. ADHD-Derived coding variation in the dopamine transporter disrupts microdomain targeting and trafficking regulation. J. Neurosc. 32(16):5385-97. (2012).53. Erreger, K., Davis, AR., Poe, AM., Greig, NH., Stanwood, GD., Galli A. Physiol Behav. 106(4):574-8. (2012).54. Khelashvili, G., Galli, A., Weinstein, H. Phosphatidylinositol 4,5-biphosphate (PIP(2)) lipids regulate the phosphorylation of syntaxin N-terminus by modulating both its position and local structure. Biochemistry. 39:7685-7698. (2012).55. Graham, DL., Erreger, K., #Galli, A., #Stanwood, GD. GLP-1 analog attenuates cocaine reward. Mol. Psychiatry. 18(9):961-2. (2012). # These authors contributed equally to this work.56. Dixit, M., Kim, S., Matthews, GF., Erreger. K., Galli. A., Cobb, CE., Hustedt, EJ., Beth AH. Structural arrangement of the intracellular Ca2+ binding domaims of the cardiac Na+/Ca2+ exchanger (NCX1.1): Effects of Ca2+ binding. J. Biol. Chem. 288(6):4194-207. (2013).57. Hamilton PJ, Campbell NG, Sharma S, Erreger K, Herborg Hansen F, Saunders C, Belovich AN; NIH ARRA Autism Sequencing Consortium, Sahai MA, Cook EH, Gether U, McHaourab HS, Matthies HJ, Sutcliffe JS, Galli A. De novo mutation in the dopamine transporter gene associates dopamine dysfunction with autism spectrum disorder. Mol Psychiatry. 18(12):1315-23. (2013).58. Buchmayer, F., Schicker, K., Geier, P., Stübiger, G., Hamilton, PJ., Jurik, A., Stockner, T., Steinkellner, T, Yang, J., Montgomery, T., Holy, M., Hofmaier, T., Winkler, M., Kudlacek, K., Matthies, HJG., Ecker, GF., Bochkov, V., Galli, A., Boehm, S., Sitte, HH. Amphetamine actions at the serotonin transporter rely on the availability of phosphatidylinositol-4,5-bisphosphate. Proc. Natl. Acad. Sci. 110(28):11642-7. (2013).59. Hamilton P.J., Campbell N.G., Sharma S., Erreger K., Hansen F.H., Saunders C., Belovich A.N., Sahai M.A., Cook E.H., Gether U., McHaourab H.S., Matthies H.J., Sutcliffe J.S., Galli, A. (2013) Drosophila melanogaster: a novel animal model for the behavioral characterization of autism-associated mutations in the dopamine transporter gene. Mol. Psychiatry. 18(12):1235. (2013).60. Saunders, C., Siuta, M., Davis, A., Robertson, S., Sauer, J., Veenstra-Vanderweele, JM., Niswender, KD., Galli, A. Neuronal deletion of rictor in mice leads to serotonin receptor upregulation and desensitization. Neuroch. Inter. 73:113-21. (2014).61. Hamilton P.J., Belovich A.N., Khelashvili G., Saunders C., Erreger K., Javitch J.A., Sitte H.H., Weinstein H., Matthies H.J., Galli A. PIP2 regulates psychostimulant behaviors through its interaction with a membrane protein. Nat. Chem. Biol. 10(7):582-9. (2014)62. Reddy, IA., Wasserman, DH., Ayala, JE., Hasty, AH., Abumrad, NN., Galli A. Striatal dopamine homeostasis is altered in mice following Roux-en-Y gastric bypass surgery. ACS Chem. Neurosci. 5(10):943-51. (2014)63. Hansen, FH., Skj?rringe, T., Yasmeen, S., Arends, NV., Sahai, M., Erreger, K., Andreassen, TF., Neergheen, V., Karlsborg, M., Newman, AH., Pope, S., Heales, S., Friberg, L., Pinborg, LH., Loland, C., Shi, L., Weinstein, H., Galli, A., Hjermind, LE., M?ller, LB., Gether, U. Functional dopamine transporter deficiency associated with adult parkinsonism and ADHD. Journal of Clinical Investigation. 124(7):3107-20. (2014).64. Bowton E., Saunders C., Reddy I.A., Campbell N.G., Hamilton P.J., Henry L.K., Coon H., Sakrikar D.J., Veenstra-VanderWeele J.M., Blakely R.D., Sutcliffe J., Matthies J.G., Erreger K., Galli A. Dopamine transporter (DAT) coding variant Ala559Val associated with attention deficit hyperactivity disorder (ADHD) regulates AMPH-induced DAT trafficking. Translational Psychiatry. (4), e464; doi:10.1038/tp.2014.90. (2014).65. Hamilton P.J., Shekar A., Belovich A.N., Bibus Christianson N., Campbell N.G., Sutcliffe J.S., Galli A., Matthies H.J.G., Erreger K. Zn2+ reverses functional deficits in a de novo dopamine transporter variant associated with autism spectrum disorder. Molecular Autism. 6:8. doi: 10.1186/s13229-015-0002-7. eCollection 2015. (2015).66. Cartier E., Hamilton P.J., Javitch J.A., Ulery-Reynolds P.G., Matthies H.J., Erreger K., Galli A. Autism-associated variants implicate syntaxin 1 phosphorylation and interaction with the dopamine transporter in dopamine neurotransmission and behaviors? EBioMedicine (Lancet). 2(2):135-146 (2015).67. Bellot, M., Galandrin, S., Boularan, C., Matthies, H.J., Despas, F., Denis, C., Javitch, J.A., 68. Mazères, S., Sanni, S.J., Pons, V., Seguelas, MH, Hansen, J.L., Pathak, A., Galli, A., Sénard, JM., Galés, C. Dual agonist occupancy of the AT1-R/2C-AR heterodimer provides a new original Gs/PKA-associated functional entity regulating sympathetic activity. Nat. Chem. Biol. 11(4):271-9. (2015).68. Dadalko, OI., Siuta, M., Poe, A., Erreger, K., Matthies, HJ., Niswender, K.,?Galli,?A. mTORC2/rictor signaling disrupts dopamine-dependent behaviors via defects in striatal dopamine neurotransmission. J. Neurosci. 35(23):8843-54. (2015).69. Saunders, C., Galli, A. Insights in how amphetamine ROCKs (Rho-associated containing kinase) membrane protein trafficking. Proc. Natl. Acad. Sci. U S A. 112(51):15538-9. (2015).70. S?rensen, G., Reddy, IA., Weikop, P., Graham, DL., Stanwood, GD., Wortwein, G., Galli, A., Fink-Jensen, A. The glucagon-like peptide 1 (GLP-1) receptor agonist exendin-4 reduces cocaine self-administration in mice. Physiol. Behav. 149:262-8. (2015).71. Dadalko, IO., Niswender, K., GalliA. Impaired mTORC2 signaling in catecholaminergic neurons exaggerates high fat diet-induced hyperphagia. Heliyon. 10.1016/j.heliyon.2015.e00025. (2015).72. Reddy, IA., Pino, JA., Weikop, P., Osses, N., S?rensen, G., Bering, T., Valle, C., Bluett, RJ., Erreger, K., Wortwein, G., Reyes, JG., Graham, D., Stanwood, GD., Hackett, TA., Patel, S., Fink-Jensen, A., Torres, GE., Galli, A. Glucagon-like peptide 1 receptor activation regulates cocaine actions and dopamine homeostasis in the lateral septum by decreasing arachidonic acid levels. Translational Psychiatry. 17;6:e809. doi: 10.1038/tp.2016.86. (2016).Reviews1. DeFelice, L.J., Galli, A. Electrophysiological analysis of transporter function. Advances in Pharmacology. 42: 186-190. (1997). 2. DeFelice, L.J., Galli, A. Fluctuation analysis of norepinephrine and serotonin transporter currents. In: Amara, S.G. ed. Neutransmitter Transporters: A Volume of Methods in Enzymology. Academic Press, Inc. San Diego. 296: 578-593. (1998). 3. Blakely, R.D., Ramamoorthy, S., Schroeter, S., Qian, Y., Apparsundaram, S., Galli, A., DeFelice, L.J. Regulated phosphorylation and trafficking of antidepressant-sensitive serotonin transporter proteins. Biol. Psychiatry. 44: 169-178. (1998).4. Sulzer, D., Kahlig, K.M., Schmitz, Y., Saunders, C., Galli, A. Amperometric recording of amphetamine-induced dopamine efflux: “Transmembrane Transporters”. A Volume of John Wiley and Son, Inc. New York. (2002). 5. Galli, A., Sulzer D. Dopamine transport currents are promoted from curiosity to physiology. Trends in Neuroscience. 26(4):173-176. (2003). 6. Kahlig, K.M., Galli, A. Regulation of dopamine transporter function and plasma membrane expression by dopamine, amphetamine, and cocaine. European J. of Pharmacology. 479: 153-158. (2003).7. Galli, A., Blakely, R.D., DeFelice, L.J. Neurotransmitter Transporters. Encyclopedia of Biological Chemistry. 3:37-40. (2004).7. Sulzer, D., Sonders, M., Poulsen, N. Galli, A. Mechanisms of neurotransmitter release by amphetamines. Progress in Neurobiology 74(6): 406-433. (2005).8. Blakely, R.D., DeFelice, L.J. Galli, A. Biogenic amine neurotransmitter transporters: just when you thought you knew them. Physiology 20: 225-231. (2005).9. Williams, J.M., Galli, A. The dopamine transporter: A vigilant border control for psychostimulant action. A chapter in: Handbook of experimental pharmacology. Neurotransmitter Transporters (vol). Springer-Verlag, New York. Handb. Exp. Pharmacol. 175:215-32. (2006).10. Robertson, S. D., Matthies, H. J.G., Galli, A. A Closer Look at Amphetamine-Induced Reverse Transport and Trafficking of the Dopamine and Norepinephrine Transporters, Mol. Neurobiol. 2009 39:73-80. (2009).11. Niswender KD., Daws LC., Avison MJ., Galli A. Insulin regulation of monoamine signaling: pathway to obesity. Hot Topics. Neuropsychopharmacology. 36(1):359-60. (2011).12. Daws LC., Avison MJ., Robertson SD., Niswender KD., Galli A., Saunders, C. Insulin signaling and addiction. Neuropharmacology. 61(7):1123-8. (2011).13. Reddy IA., Stanwood GD., Galli A. Moving beyond energy homeostasis: new roles for glucagon-like peptide-1 in food and drug reward. Neurochem Int. 73:49-55. (2014).INVITED LECTURES:1994:Department of Physiology, Torin, Italy: "Long opening of high-threshold Ca2+ channels triggered by action potential in neuronal cells".Department of Physiology, Milan, Italy: "Current fluctuations in norepinephrine transporters".1996:November: Department of Physiology, Milan, Italy: " Drosophila serotonin transporters have high voltage-dependent uptake coupled to a serotonin-gated ion channel".December: Institute "Mario Negri", Milan, Italy: "Drosophila serotonin transporters have high voltage-dependent uptake coupled to a serotonin-gated ion channel".1998:January: University of Manchester, School of Pharmacy, Manchester, England: “Amperometric recordings of channel-like activity in norepinephrine transporters”.January: Institute "Mario Negri", Milan, Italy: " Amperometric analysis of NE transporters ".February: 1998 Biophysical Society Meeting: Platform session “Molecular Structure and Biophysics of neurotransmitter transporters”. “Amperometric analysis of NE transporters”.February: University of Texas H.S.C. San Antonio, Department of Pharmacology: " Amperometric analysis of NE transporters ".March: Columbia University, Department of Pharmacology: “Patch-clamp and Amperometric Recordings of Channel-like Activity in Norepinephrine Transporters”.April: Boston University School of Medicine, Department of Pharmacology and Experimental Therapeutics: “Patch-clamp and Amperometric Recordings of Channel-like Activity in Norepinephrine Transporters”.April: Children’s Hospital of Philadelphia, Division of Neurology: “Patch-clamp and Amperometric Recordings of Channel-like Activity in Norepinephrine Transporters”.June: University of Pennsylvania, Department of Pharmacology: “Patch-clamp and Amperometric Recordings of Channel-like Activity in Norepinephrine Transporters”.1999.July: Oxford, U.K: Gordon Research Conference on Catecholamines: “Channel functions of DA and NE transporter”.July: London, U.K: Eli Lilly and Co: “Channel functions of DA and NE transporter”.December: Acapulco, Mexico: ACNP meeting: “Channel functions of DA and NE transporter”.2000:February: Texas A&M University in College Station, Department of Pharmacology: " Amphetamine: a W(H)ole Agonist of the Human Dopamine Transporter ". April: University of Texas H.S.C. San Antonio, Department of Pediatrics: " Amphetamine: a W(H)ole Agonist of the Human Dopamine Transporter ".April: University of California at S.F., Gallo Clinic and Research Center: "Amphetamine: a W(H)ole Agonist of the Human Dopamine Transporter ".July: Connecticut College, CT: Gordon Research Conference on Membrane Transport Proteins: “Amphetamine Regulation of Dopamine Transport”.December: Steamboat Springs, CO: Winter Conference on Brain Research: “Amphetamine Regulation of Dopamine Transport”.2001:February: University of Texas Medical Branch at Galveston, Department of Pharmacology & Toxicology : “Amphetamine Regulation of Dopamine Transport”.July: Tucson, AZ. FASEB Summer Research Conferences on New Perspectives in Transport Biology: “Amphetamine Regulation of Dopamine Transport”.August: Finch University of Health Sciences/Chicago Medical School: “The docking, sinking and rescue: amphetamine and insulin regulation of dopamine transporter activity”.September: Vanderbilt University, Department of Molecular Physiology and Biophysics: “The docking, sinking and rescue: amphetamine and insulin regulation of dopamine transporter activity”.2002:January: NIDA: Intracellular Protein Trafficking and Drugs of Abuse: “The docking, sinking and rescue: amphetamine and insulin regulation of dopamine transporter activity”.January: Snowmass Village, CO: Winter Conference on Brain Research : “The docking, sinking and rescue: amphetamine and insulin regulation of dopamine transporter activity”.April: Sicily, Italy: International School of Biophysics “ A. Borsellino”: Excitability, Secretion, and Transport: Molecules to Medication. “The docking, sinking and rescue: amphetamine and insulin regulation of dopamine transporter activity”.April: New Orleans, LA. Experimental Biology Meeting (ASPET): Mechanisms of Amphetamines in Eliciting and Regulating Monoamine Transport: “The docking, sinking and rescue: amphetamine and insulin regulation of dopamine transporter activity”. September: Vanderbilt University, Membrane Biology Group: “Drug trafficking: new surveillance at the borders”.2003:January: NIDA: “Drug trafficking: new surveillance at the borders”.November: New Orleans, LA. Neuroscience Meeting. NIDA Symposium: “Dopamine Transporter: Are psychostimulants in your neighborhood forcing you to move?”.December: Weill Medical College of Cornell University: “Monitoring dopamine transporter activity”.2004:March: Washington, D.C. Third Annual NIH Live Cell Imaging Seminar. NIH: “DAT trafficking: vigilant border patrol”.May: Vanderbilt University Summer Conferences (Genomics of Reward and Addiction): “Combining amperometry, physiology and imaging”. October: Les Diablerets, Switzerland. Gordon Research Conference on Membrane Transport Proteins.: “DAT trafficking: vigilant border patrol”. November: Texas Tech University H.S.C. at Lubbock: “Pulses of pleasure: Amphetamine Induces Dopamine Efflux Through a Transporter Channel”. December: UAMS at Little Rock. “DAT trafficking: vigilant border patrol”.2005:April: San Diego, CA. Experimental Biology Meeting (ASPET). Ray Fuller Symposium: “Molecular biophysics of amphetamine action”.May: Erice, Sicily, Italy: International School of Biophysics “ A. Borsellino”: Excitability, Secretion, and Transport: Molecules to Medication.July: Saxtons River, VE. FASEB Summer Research Conferences on New Perspectives in Transport Biology. Section Chair: “Pulses of pleasure: Amphetamine Induces Dopamine Efflux through a Transporter Channel”July: Proctor Academy Andover, NH. Gordon Research Conference on Catecholamines: “Pulses of pleasure: Amphetamine Induces Dopamine Efflux through a Transporter Channel”August: Cold Spring Harbor Laboratory, NY. Cellular Biology of Addiction: “Molecular biophysics of amphetamine action”.August: Innsbruck, Austria. International Society for Neurochemistry: “Molecular biophysics of amphetamine action”.November: Washington D.C. Fifteenth Neuropharmacology conference, New Perspectives in Neurotransmitter Transporter Biology: “Molecular biophysics of amphetamine action”.2006:August: University of New England, ME. Gordon Research Conference on Membrane Transport Proteins. Section Chair. September: University of Vienna, Austria. “Molecular biophysics of amphetamine action”.October: Department of Pharmacology, Columbia University, NY. “Probing the?action of amphetamine: the need for speed".October: Department of Psychiatry, Columbia University, NY. “Securing the border: insulin regulation of?the actions of amphetamine”.November: Department of Pharmacology, University of Colorado HSC. Aurora, CO. “Probing the?action of amphetamine: the need for speed".December: Department of Physiology, University of Miami, FL. “Probing the?action of amphetamine: the need for speed".2007:January: Department of Physiology, Stony Brook University, NY. “Probing the?action of amphetamine: the need for speed".March: Department of Physiology, University of Texas HSC, TX. “Securing the border: insulin regulation of?the actions of amphetamine”.March: DIBIT, San Raffaele Scientific Institute, Milan, Italy. “Probing the?action of amphetamine: the need for speed".December: Department of Pharmacology, University of Michigan, Ann Arbor, MI. “Securing the border: insulin regulation of?the actions of amphetamine”.2008:August: Il Ciocco, Italy. Gordon Research Conference on Membrane Transport Proteins. "Influx and Efflux in the Dopamine Transporter".September: University of Vienna, Austria. SFB-Symposium. “How sweet is DAT. Insulin regulation of dopamine transport”.September: Vanderbilt University. Diabetes, Endocrinology and Metabolism Grand Rounds. “Our sweet tooth regulates dopamine clearance: The “ins” and “outs” of the dopamine transporter in diabetes and obesity”.December: American College of Neuropsychopharmacology Scottsdale, Arizona. Symposium. “PI3K/Akt signaling in dopaminergic action”.2009:April: Experimental Biology Meeting, New Orleans, LA. Julius Axelrod Symposium. “The Neurotransmitter End Game”.August: SB35 Transporter Meeting, Vienna, Austria. Section Chair.August: Brain Institute, Vienna, Austria. The fat, the NET, and the DAT: homeostasis of monoamines in the obese and lean brain.October: Department of Pharmacology, University of North Dakota, ND. The fat, the NET, and the DAT: homeostasis of monoamines in the obese and lean brain.October: Department of Neuroscience. UT Southwestern, Dallas, TX. “The Fat is not good for DAT. Regulation of dopamine clearance in diabetes and obesity”. 2010:January: Winter Conference on Brain Research. Breckenridge, Colorado. “Dopamine signaling and disease: wormholes, flytraps, organic farmers and ouseketeers in the pursuit of new medications”. August: SB35 Transporter Meeting, Vienna, Austria. Section Chair.August: University of New England, ME. Gordon Research Conference on Membrane Transport Proteins. Section Chair. September: Panum Institute, University of Copenhagen, Copenhagen, Denmark. “Obesity and neuropsychiatric disorders: a brain AKTing badly”.September: Scandinavian conference on Molecular physiology of channels and transporters Sigtunastiftelsen, Stockholm. Key note speaker. “SNAREing dopamine transporter function”. November: Department of Pharmacology, UPenn, Philadelphia. “Obesity and neuropsychiatric disorders: a brain AKTing badly”.2011:September: SB35 Transporter Meeting, Vienna, Austria. Plenary Lecture. “Syntaxin: teaching an old dog new tricks”.November: Department of Physiology and Biophysics, Case Western Reserve University. “How the Big GULP Cures the Fat Brain: Striatal Insulin Resistance and GLP-1 Signaling”. December: American College of Neuropsychopharmacology, Hilton Waikoloa Village, Hawaii. “How the Big GULP Cures the Fat Brain: Striatal Insulin Resistance and GLP-1 Signaling”.December: American College of Neuropsychopharmacology, Hilton Waikoloa Village, Hawaii. “Dysregulation of the norepinephrine transporter sustains cortical hypodopaminergia and schizophrenia-like behaviors in neuronal rictor null mice”.2012:September: Lieber Institute for Brain Development, Baltimore. “Dopamine, Clean Up Your “AKT”! Restoring Insulin Signaling in Brain”. October: Sanford Burnham Medical Research Institute, Orlando. “How to “AKT” Around Fat Food: Just Say “NO” with GLP-1”. October: NIDA: Frontiers in Addiction Research, New Orleans. “How to “AKT” Around Fat Food: Just Say “NO” with GLP-1”. November: UMASS, Worcester. “DAT N-Terminus: “Levering Transport Function, Lipid Interactions and Neuropsychiatric Disorders”. March: 5th CCHD Workshop, Vienna. “Metabolic imprinting of Monoamine Neurotransmission in Obesity and Diabetes.March: Brain Institute, Vienna. “Metabolic imprinting of Monoamine Neurotransmission in Obesity and Diabetes.July: Gordon GRC in Les Diablerets, Switzerland. “DAT N-Terminus: “Levering Transport Function, Lipid Interactions and Neuropsychiatric Disorders”. September: Catecholamine Symposium, Asilomar. “Levering Transport Function, Lipid Interactions and Neuropsychiatric Disorders”. 2013March: University of Kentucky, Lexington, T32 Symposium. Plenary Lecture. “Location, Location, Location: the Key Regulation of Dopamine Homeostasis and Amphetamine Actions”.April: Illinois State, Normal. “Location, Location, Location: the Key Regulation of Dopamine Homeostasis and Amphetamine Actions”.April: Cancun, Mexico. “Location, Location, Location: the Key Regulation of Dopamine Homeostasis and Amphetamine Actions”.May: Alghero, Italy. “The Role of Rare Variants in Identifying Susceptibility Genes and Pathways in Autism”.May: Alghero, Italy. “Location, Location, Location: the Key Regulation of Dopamine Homeostasis and Amphetamine Actions”.November: American College of Neuropsychopharmacology, Fort Lauderdale. “Is the Obese Brain “Akt”ing Schizophrenic?”.November: University of Pittsburg, Pittsburg . “The Dopamine Transporter Sucks…or maybe not in Autism and Psychostimulant Abuse”.2014April: University of Florida, Gainesville. “Tap “DAT” Neuropsychiatric Disorder”.April: Experimental Biology, San Diego. Science of Addiction. “PIP2 Regulates Psychostimulant Behaviors via a Membrane Protein Interaction”.June: University of Texas, Galveston. “Neuropsychiatric Disorders Move Flies to a PIP2 Groove”August: Department of Anatomy and Neurobiology, University of Maryland, Baltimore. “Neuropsychiatric Disorders Move Flies to a PIP2”.September: SB35 Transporter Meeting, Vienna, Austria. “Tap “DAT” Neuropsychiatric Disorder”.December: American College of Neuropsychopharmacology, Phoenix, Arizona. “Aberrant Akt Signaling Disrupts Central DA Homeostasis and Amphetamine induced Behaviors”. 2015August: Sunday River, Newry, ME. Gordon Research Conference on Catecholamines. “Bariatric Surgery and Cocaine Reward”.September: SB35 Transporter Meeting, Vienna, Austria. Section Chair.2016June: Il Ciocco, Italy. Gordon Research Conference on Membrane Transport Proteins. "Failure to Prime the Dopamine 'Pump' in Autism".June: Il Ciocco, Italy. Gordon Research Conference on Membrane Transport Proteins. Section Chair.July: FENS Forum of Neuroscience. Copenhagen, Denmark. "Failure to Prime the Dopamine 'Pump' in Autism". ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download